Draft guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs) - Revision 1
Requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs) - Scientific guideline
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 11, Status: Authorised
Scientific advice and protocol assistance adopted during the CHMP meeting 8-11 December 2025
Investigation and assessment of cardiovascular safety of anticancer medicinal products
Reflection paper on investigation and assessment of cardiovascular safety of anticancer medicinal products
Opinion/decision on a Paediatric investigation plan (PIP): Kengrexal, cangrelor (tetrasodium), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: EMA/PE/0000239079
Human medicines European public assessment report (EPAR): Opatanol, olopatadine, Date of authorisation: 16/05/2002, Revision: 26, Status: Authorised
Eighth European Medicines Agency (EMA) and Medicines for Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 15 December 2025, 15:00 (CET) to 15 December 2025, 17:00 (CET)